Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms (SCENT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01716117 |
Recruitment Status :
Completed
First Posted : October 29, 2012
Results First Posted : July 23, 2019
Last Update Posted : December 19, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Brain Aneurysm | Device: Surpass Flow Diverter | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 213 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | The SCENT Trial is a multi-center, prospective, non-randomized trial. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT Trial) |
Actual Study Start Date : | October 25, 2012 |
Actual Primary Completion Date : | December 11, 2016 |
Actual Study Completion Date : | July 7, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Surpass Flow Diverter
The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
|
Device: Surpass Flow Diverter
Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
Other Names:
|
- mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any Subsequent Treatment of the Target Aneurysm at the 12 Month Follow up Visit. [ Time Frame: 12 months ]Percent of subjects with 100% occlusion of the aneurysm without clinically significant stenosis (defined as less than or equal to 50% stenosis) of the parent artery based on core lab evaluation of the 12 month follow up angiogram and without any subsequent treatment of the target aneurysm at the 12 month follow up visit.
- mITT Primary Safety Endpoint. Based on Subjects Experiencing Neurologic Death or Major Ipsilateral Stroke Through 12 Month Follow-up. [ Time Frame: 12 months ]Subjects experiencing neurologic death or major ipsilateral stroke through 12 months.
- Raymond-Roy Score Per Core Lab Assessment Based on Device Apposition at 12 Months Post-Procedure [ Time Frame: 12 months ]The Raymond-Roy intracranial aneurysm occlusion classification was used to assess the rate of aneurysm occlusion at the time of primary endpoint assessment (12 months). Occlusion rates were reported as Class I: complete obliteration (best); Class II: residual neck; Class III: residual aneurysm (worse).
- Clinical Events Committee (CEC) Adjudicated Rate of Minor Strokes Through 12 Month Follow-Up [ Time Frame: 12 Months ]Patients with minor strokes through 12 months
- Subgroup Analysis of Primary Effectiveness Endpoint Based on Subject Age ≥ 65 Years Versus < 65 Years in mITT Population [ Time Frame: 12 Months ]Primary effectiveness by age group
- CEC Adjudicated Primary Effectiveness Endpoint Outcomes for Giant and Non-Giant (Large) Intracranial Aneurysms Through 12 Month Follow-Up - mITT Population [ Time Frame: 12 Months ]Primary effectiveness by intracranial aneurysm size
- Number of Surpass Streamline Flow Diverters Implanted Per Subject in SCENT Trial - mITT and Roll-In Populations [ Time Frame: 12 Months ]Number of devices implanted in subjects by study population

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 19 to 80 years
- Subject or legal representative is willing and able to give informed consent
- Subject has a single targeted intracranial aneurysm
- Subject agrees to return to the treating Investigator for all scheduled follow up visits and is capable of returning to the hospital for follow up
Exclusion Criteria:
- Known allergy or contraindication to aspirin, clopidogrel/Plavix, heparin, local or general anesthesia
- Known history of life threatening allergy to contrast dye
- Known allergy to nickel, chromium cobalt, tungsten or platinum
- Subject has documented resistance to clopidogrel/Plavix
- Major surgery within previous 30 days or planned in the next 120 days after enrollment date
- Previous intracranial implant associated with the symptomatic distribution within the past 12 weeks prior to treatment date
- Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to treatment date
- Any previous stenting of parent artery at or proximal to the aneurysm where it would interfere with the placement and proper apposition of the device
- Any previous coiling where it would interfere with the placement and proper apposition of the device
- Platelet count less than 100,000 cells/mm3 or known platelet dysfunction
- More than one intracranial aneurysm (IA) that requires treatment within 12 months
- Asymptomatic extradural aneurysms requiring treatment
- Contraindication to CT scan or MRI
- Severe neurological deficit that renders the subject incapable of living independently
- Unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days)
- Evidence of active infection at the time of treatment
- Dementia or psychiatric problem that prevents the patient from completing required follow up
- Co-morbid conditions that may limit survival to less than 24 months
- Serum creatinine greater or equal to 2.5 mg/dL
- Female subjects who are pregnant or planning to become pregnant within the study period
- Subject with anatomy not appropriate for endovascular treatment due to severe intracranial vessel tortuosity or stenosis
- Extra-cranial stenosis or parent vessel with stenosis greater than 50% in the area proximal to the aneurysm
- Other known serious concurrent medical conditions
- History of intracranial vasospasm not responsive to medical therapy
- Subject with an intracranial mass, or is undergoing radiation therapy for carcinoma or sarcoma of the head or neck region
- Subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (INR) greater than 1.5, or will refuse blood transfusions
- Subject had a subarachnoid hemorrhage within 30 days prior to the enrollment date
- Subject has a non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm
- Inability to understand the study or a history of non-compliance with medical advice
- Current use of illicit substance
- Enrollment in another trial involving an investigational product
- Subject has a need for long-term use of anticoagulants (i.e., Warfarin, Dabigatran)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01716117

Principal Investigator: | Ricardo A Hanel, MD, PhD | Lyerly Baptist Medical Center, Jacksonville, Florida | |
Principal Investigator: | Philip M Meyers, MD | Columbia University |
Responsible Party: | Stryker Neurovascular |
ClinicalTrials.gov Identifier: | NCT01716117 |
Other Study ID Numbers: |
SP-04 |
First Posted: | October 29, 2012 Key Record Dates |
Results First Posted: | July 23, 2019 |
Last Update Posted: | December 19, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is no plan to make IPD information available to other researchers. Blinded study data by mITT and Roll-in cohorts may be made available to SCENT researchers post publication of the primary study results. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Large aneurysm Giant aneurysm Wide neck aneurysm |
Intracranial Aneurysm Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases Cerebrovascular Disorders Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Calcium Carbonate Antacids Molecular Mechanisms of Pharmacological Action Gastrointestinal Agents |